Abstract
Octreotide effectively maintained blood glucose levels in diazoxide-unresponsive CHI patients without serious adverse effects, across all subtypes. Our study suggests that intermediate octreotide dosing is associated with a lower incidence of adverse events. We recommend close monitoring of patients receiving octreotide, especially during the initiation phase and when higher doses are administered. •Octreotide is a commonly used second line treatment for patients with congenital hyperinsulinism. •The administration of octreotide is frequently associated with gastrointestinal adverse events. •Our study indicates that octreotide is used without serious adverse effects to maintain blood glucose levels in infants with congenitalhyperinsulinism who are otherwise in good health. •The incidence of adverse events in patients treated with octreotide is dose-dependent.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call